Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Interest & Investment Income: 2011-2025

Historic Interest & Investment Income for Fennec Pharmaceuticals (FENC) over the last 14 years, with Sep 2025 value amounting to $152,000.

  • Fennec Pharmaceuticals' Interest & Investment Income fell 70.54% to $152,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $958,000, marking a year-over-year decrease of 31.47%. This contributed to the annual value of $1.7 million for FY2024, which is 281.41% up from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Interest & Investment Income stood at $152,000, which was down 11.11% from $171,000 recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Interest & Investment Income registered a high of $570,000 during Q2 2024, and its lowest value of $9,000 during Q1 2022.
  • In the last 3 years, Fennec Pharmaceuticals' Interest & Investment Income had a median value of $171,000 in 2025 and averaged $243,818.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Interest & Investment Income surged by 1,177.78% in 2023, and later slumped by 70.54% in 2025.
  • Fennec Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $13,000 in 2021, then soared by 84.62% to $154,000 in 2022, then declined by 25.32% to $115,000 in 2023, then spiked by 246.96% to $399,000 in 2024, then tumbled by 70.54% to $152,000 in 2025.
  • Its Interest & Investment Income stands at $152,000 for Q3 2025, versus $171,000 for Q2 2025 and $236,000 for Q1 2025.